TY  - GEN
AU  - Kameshwari, J. S.
AU  - Devde, Raju
TI  - Case report on toxic epidermal necrolysis with etoricoxib
PY  - 2015///
CY  - Mumbai
PB  - Wolter Kluwer
KW  - PHARMACOLOGY
N2  - Etoricoxib is a selective cyclo-oxygenase 2 (COX-2) enzyme inhibitor and is exploited for its analgesic activity in various disease conditions like osteoarthritis, gouty arthritis, acute pain including postoperative dental pain and primary dysmenorrhea, etc. Although highly efficacious in pain management the safety profile of this COX-2 inhibitor is yet to be established in a broader sense. Short-term clinical trials and postmarketing surveillance have shown a very rare incidence of very serious skin reactions like Steven Johnson syndrome or toxic epidermal necrolysis (TEN). In this case report, we summarize regarding a patient who developed TEN after treatment with etoricoxib for osteoarthritis that later resolved in 15 days after withdrawal and symptomatic treatment
UR  - https://journals.lww.com/iphr/fulltext/2015/47020/a_case_report_on_toxic_epidermal_necrolysis_with.20.aspx
ER  -